Eli Lilly and Company (ETR:LLY)
Germany
· Delayed Price · Currency is EUR | Market Cap | 595.85B |
| Revenue (ttm) | 45.34B |
| Net Income (ttm) | 10.28B |
| Shares Out | n/a |
| EPS (ttm) | 11.37 |
| PE Ratio | 57.99 |
| Forward PE | 31.10 |
| Dividend | 5.18 (0.78%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 215 |
| Average Volume | 2,765 |
| Open | 663.50 |
| Previous Close | 660.70 |
| Day's Range | 659.10 - 663.90 |
| 52-Week Range | 604.60 - 888.30 |
| Beta | 0.39 |
| RSI | 45.45 |
| Earnings Date | Aug 7, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with Lilly and Novo.
Tech stocks soar: Semiconductors and software lead market gains
Sector Overview: Tech Takes the Lead The US stock market exhibited a remarkable tilt towards the technology sector today, with tech giants and semiconductors driving considerable gains. The sector at ...
Top 50 High-Quality Dividend Stocks For July 2025
I track 50 high-quality dividend growth stocks to identify opportune investments, updating valuation ratings daily to focus on attractive opportunities. In this turbulent year, my investable universe ...
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
Top 15 High-Growth Dividend Stocks For July 2025
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, tho...
CVS drops Lilly's Zepbound
CNBC's Angelica Peebles reports on news regarding CVS.
Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report
Novo Nordisk A/S’ (NYSE: NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its obesity drug Wegovy . As rival Eli Lilly and Co.’s (NYSE: LLY) Zepbound gai...
Major insurance changes are coming to GLP-1 drugs for weight loss. Heres how that could affect patients
Starting July 1, CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CV...
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.
4 stocks to watch on Monday: PLTR, LLY, HD, AMZN
SA analyst upgrades/downgrades: ADBE, CMG, COIN, LLY
Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs
Against a backdrop of regulatory scrutiny, with Spain investigating Novo Nordisk for alleged covert advertising of its popular weight-loss drugs, the U.K. is initiating research to determine if geneti...
Dividend Roundup: Eli Lilly, Mastercard, AT&T, Cisco, and more
Eli Lilly: I've Learned Not To Fight Against The Market (Downgrade)
Eli Lilly seen as the stronger bet amid escalating competition with Novo in India
The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical frontiers. As rising obesity an...
Eli Lilly to bring Mounjaro pen in India to rival Novo Nordisk’s Wegovy
Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy
Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk...
Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate
Weight loss and diabetes jabs linked to potentially fatal side effect
Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator.
US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows
Although glucagon-like peptide-1 (GLP-1) agonists have shown promising results in reducing weight and cardiovascular risks, new data reveals that many U.S. adults struggle to stay on long-term treatme...
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.
What's Going On With Viking Therapeutics Stock On Wednesday?
Viking Therapeutics, Inc. (NASDAQ: VKTX) on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company’s dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-depende...
Eli Lilly's olomorasib granted orphan drug designation for NSCLC type
Novo Nordisk’s Wegovy debuts in India: How it works, who it’s for, and how much it costs
Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy is a once-weekly injectable using a user-friendly FlexTouch pen. Targetin...